Cisen Pharmaceutical Co Ltd (SHG:603367) — Market Cap & Net Worth
Market Cap & Net Worth: Cisen Pharmaceutical Co Ltd (603367)
Cisen Pharmaceutical Co Ltd (SHG:603367) has a market capitalization of $967.28 Million (CN¥6.61 Billion) as of September 24, 2026. Listed on the SHG stock exchange, this China-based company holds position #9172 globally and #2305 in its home market, demonstrating a 3.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cisen Pharmaceutical Co Ltd's stock price CN¥14.60 by its total outstanding shares 452754129 (452.75 Million). Also see 603367 asset base for a full breakdown of the balance sheet.
Cisen Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Cisen Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $1.18 Billion to $967.28 Million (-0.37% CAGR). Also see cash flow conversion of Cisen Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Cisen Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cisen Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 603367 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.33x
Cisen Pharmaceutical Co Ltd's market cap is 0.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.72x
Cisen Pharmaceutical Co Ltd's market cap is 2.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.18 Billion | $2.96 Billion | $367.22 Million | 0.40x | 3.22x |
| 2018 | $909.45 Million | $3.81 Billion | $503.54 Million | 0.24x | 1.81x |
| 2019 | $1.01 Billion | $4.11 Billion | $514.58 Million | 0.25x | 1.96x |
| 2020 | $860.71 Million | $3.67 Billion | $438.78 Million | 0.23x | 1.96x |
| 2021 | $843.37 Million | $3.78 Billion | $334.15 Million | 0.22x | 2.52x |
| 2022 | $816.16 Million | $4.07 Billion | $349.96 Million | 0.20x | 2.33x |
| 2023 | $969.93 Million | $4.46 Billion | $521.34 Million | 0.22x | 1.86x |
| 2024 | $910.30 Million | $3.98 Billion | $508.91 Million | 0.23x | 1.79x |
| 2025 | $1.15 Billion | $3.44 Billion | $421.25 Million | 0.33x | 2.72x |
Competitor Companies of 603367 by Market Capitalization
Companies near Cisen Pharmaceutical Co Ltd in the global market cap rankings as of September 24, 2026. Review 603367 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cisen Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #586 globally with a market cap of $46.44 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #638 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #651 globally with a market cap of $42.68 Billion USD ( CN¥291.65 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #586 | GALDERMA GROUP AG | NYSE:GALDY | $46.44 Billion | $39.83 |
| #638 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #651 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.68 Billion | CN¥45.72 |
Cisen Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Cisen Pharmaceutical Co Ltd's market cap moved from $1.18 Billion to $ 967.28 Million, with a yearly change of -0.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥967.28 Million | -15.70% |
| 2025 | CN¥1.15 Billion | +26.06% |
| 2024 | CN¥910.30 Million | -6.15% |
| 2023 | CN¥969.93 Million | +18.84% |
| 2022 | CN¥816.16 Million | -3.23% |
| 2021 | CN¥843.37 Million | -2.01% |
| 2020 | CN¥860.71 Million | -14.65% |
| 2019 | CN¥1.01 Billion | +10.88% |
| 2018 | CN¥909.45 Million | -22.98% |
| 2017 | CN¥1.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Cisen Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $967.28 Million USD |
| MoneyControl | $967.28 Million USD |
| MarketWatch | $967.28 Million USD |
| marketcap.company | $967.28 Million USD |
| Reuters | $967.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and a… Read more